Anzeige
Meldung des Tages: Kupfer vor dem Engpass: Warum Kupfer gerade zur „Nvidia“ unter den Rohstoffen wird

Teva Pharmaceutical Aktie (ADR) News

Aktie
WKN:  883035 ISIN:  US8816242098 US-Symbol:  TEVA Branche:  Pharmazeutika Land:  Israel
31,81 $
+0,15 $
+0,47%
26,892 € 23.01.26
Depot/Watchlist
Marktkapitalisierung *
31,15 Mrd. €
Streubesitz
39,66%
KGV
-15,52
Dividende
0,071 €
Dividendenrendite
0,26%
Faktor
1
Originalaktie
IL0006290147
neu: Nachhaltigkeits-Score
58 %
Weiter aufwärts? Long handeln - Jetzt mit Hebel 7,29: VH0A9A
Werbung

Teva Pharmaceutical Aktie (ADR) News

14.01.26 - GlobeNewswire
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-​related peptide (CGRP) antagonist treatment option for ...
12.01.26 - GlobeNewswire
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. ...
11.01.26 - GlobeNewswire
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 ...
05.01.26 - GlobeNewswire
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
24.12.25 - GlobeNewswire
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody's affirmed Teva's B1a rating and revised Teva's ...
19.12.25 - GlobeNewswire
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
According to the settlement agreement, the proposed biosimilar to Eylea ® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier ...
12.12.25 - GlobeNewswire
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth ...
12.12.25 - GlobeNewswire
Teva Releases Q4 2025 Aide Memoire
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on ...
09.12.25 - GlobeNewswire
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-​acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-​monthly, subcutaneous formulation, for a broad patient population 1 Olanzapine ...
04.12.25 - dpa-AFX
KORREKTUR/Pharmabranche: Engpässe bei Kinderarzneien sind gesunken
Bisherige Schritte der Politik gegen Arznei-​Engpässe in Deutschland haben aus Sicht des Pharmaverbands Pro Generika nur begrenzt geholfen. Zwar habe sich die Versorgung bei ...
04.12.25 - dpa-AFX
Pharmabranche: Keine Entspannung bei Engpässen von Kinderarzneien
Bisherige Schritte der Politik gegen Arznei-​Engpässe in Deutschland haben aus Sicht des Pharmaverbands Pro Generika nur begrenzt geholfen. Zwar habe sich die Versorgung bei ...
26.11.25 - GlobeNewswire
Teva erhält Zulassung der Europäischen Kommission für PONLIMSI® (Denosumab), ein Biosimilar zu Prolia®, und DEGEVMA® (Denosumab), ein Biosimilar zu Xgeva®
Aufgrund der positiven Stellungnahmen des Ausschusses für Humanarzneimittel (CHMP) hat die Europäische Kommission die Zulassungen für die Biosimilars PONLIMSI und ...
25.11.25 - GlobeNewswire
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP ) , the European Commission has granted marketing authorizations for Teva’s ...
21.11.25 - GlobeNewswire
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
19.11.25 - GlobeNewswire
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
First cohort features 7 real-​world challenges across R&D, manufacturing and supply chain, commercial and medical affairs  Teva's first-​ever global innovation platform aims to ...
08.11.25 - GlobeNewswire
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking ...
05.11.25 - GlobeNewswire
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
For an accessible version of this Press Release, please visit www.tevapharm.com
03.11.25 - GlobeNewswire
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis
This football season, Teva is increasing education around tardive dyskinesia (TD) by  launching ‘The Other TD’ campaign TD is a chronic movement disorder impacting one in four ...
31.10.25 - GlobeNewswire
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
21.10.25 - GlobeNewswire
Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Vermarktung von Tuznue® in Europa
Teva und Prestige geben eine Lizenz- und Liefervereinbarung für die Vermarktung des von Prestige hergestellten Arzneimittels Tuznue ® bekannt, einem Biosimilar zu Herceptin ® ...

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »